Lurasidone

  • ( 3aR, 4S, 7R, 7aS ) -2 - [ (1R, 2R ) - 2 - [4 - ( 1,2-benzisothiazol- 3-yl) - piperazin-1 - ylmethyl]- cyclohexylmethyl ] hexahydro -1H -4, 7 methanisoindol -1 ,3 -dione
  • SM- 13496
  • 367514-87-2
  • 367514-88-3 ( Lurasidonhydrochlorid )

N05AE05

Antipsychotic

Template: Infobox chemical / molecular formula search available

Lurasidon (trade name Latuda ®) is a drug which was developed as an atypical antipsychotic used to treat schizophrenia and depressive phases of bipolar disorder in the framework by the Japanese company Dainippon Sumitomo Pharma. Since 2010 it has been approved in the United States. After a positive vote in January 2014, the CHMP, the European Medicines Agency has issued a license for the EU in March 2014.

The antipsychotic activity of Lurasidon is based on a blockade of D2 and 5- HT2A receptors. In animal experiments, Lurasidon could make the negative effects of the NMDA inhibitor MK -801 reversed on memory and learning ability of rats. The service sector Datamonitor sees Lurasidon as another variant of atypical antipsychotics with limited therapeutic value.

Mid-2005, Dainippon Sumitomo Lurasidon licensed from the U.S. MSD Sharp & Dohme. However, Merck withdrew in 2006 back from the collaboration. Then Dainippon Sumitomo led the development by itself again.

CAS registry number PubChem Anatomical Therapeutic Chemical Classification System Active ingredient Dopamine receptor NMDA receptor
535270
de